The AAP 2017 Pediatric Hyper- tension guideline recommends that children or adolescents with both CKD and hypertension should be treated to lower 24-hour MAP to <50th percentile of the distribution of BP of healthy children, as measured using ABPM. They further recommend that, regardless of apparent control of BP ac- cording to of ce measurements, children and adolescents with CKD and a history of hypertension should have BP assessed by ABPM at least yearly. Additionally, this guideline recommends that children and adolescents with CKD, hypertension, and proteinuria should be treated with an ACEi or ARB, largely based on observational data.1 In the ESCAPE trial, children in both arms of the trial were given a xed-dose ACEi; therefore, the effect of ACEi per se could not be delineated. Key differences between the current and prior KDIGO recommendations in children with CKD include that the prior KDIGO guideline made a recommendation for the initiation of antihypertensive medication when the of ce SBP or DBP is consistently above the 90th percentile for age, sex, and height, whereas in the current guideline, all children with CKD and MAP consistently above the 50th percentile should be treated. 